GRT6005
Phase 2Small molecule
GRT6005 is one of 43 small molecule programs targeting Diabetic Polyneuropathy. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPreclinical
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
GRT6005
TTris Pharma, Inc.
Phase 2
Glucophage
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GRT6005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTris Pharma, Inc.